

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Trabectedin for the treatment of advanced metastatic soft tissue sarcoma

Response to consultee and commentator comments on the provisional matrix of consultees and commentators (pre-referral)

Version of matrix of consultees and commentators reviewed: Provisional matrix of consultees and commentators sent for consultation				
Summary of comments, action taken, and justification of action:				
	<i>Proposal:</i>	<i>Proposal made by:</i>	<i>Action taken:</i> Removed/Added/Not included/Noted	<i>Justification:</i>

National Institute for Health and Clinical Excellence

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of trabectedin for the treatment of advanced metastatic soft tissue sarcoma

Issue date: September 2008

1.	<p><i>Childhood Cancer & Leukaemia Group (CCLG) does not seem to be on the list of consultees - which would be important as this drug may have implications for children/teenagers with advanced metastatic STS</i></p>	<p><i>Royal College of Nursing – Paediatric Oncology Nurses Forum</i></p>	<p><i>Not added</i></p>	<p><i>The final scope states that the medication excludes ‘children & adolescents’ therefore Childhood Cancer & Leukaemia Group (CCLG) does not meet the criteria for this appraisal and subsequently have not been added.</i></p>
----	---	---	-------------------------	--

National Institute for Health and Clinical Excellence

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of trabectedin for the treatment of advanced metastatic soft tissue sarcoma

Issue date: September 2008

2.	<i>We believe that the British Sarcoma Group - the association of specialist clinicians should be a full consultee</i>	<i>Sarcoma UK</i>	<i>Added</i>	<i>This organisation's interests are closely related to the appraisal topic and as per our inclusion criteria and equalities commitments. Therefore the British Sarcoma Group have been added to the matrix under 'professional' groups</i>
----	--	-------------------	--------------	---

National Institute for Health and Clinical Excellence

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of trabectedin for the treatment of advanced metastatic soft tissue sarcoma

Issue date: September 2008